Loading patent…
AssigneeNoNO Inc.
InventorsMichael Tymianksi, Jonathan David Garman, Diana Mayor
Estimating the term…
The invention provides variants of a previously described active agent for treating stroke, Tat-NR2B9c, in which target binding characteristics are retained by inclusion of L-amino acids at the C-terminus and plasmin-resistance is conferred by inclusion of D-amino acids elsewhere. An exemplary agent has the sequence ygrkkrrqrrrklssIETDV (SEQ ID NO:62). The resulting active agents have several advantages including administration at the same time as thrombolytic agents without significant loss of activity due to plasmin digestion. The resulting agents are also more suitable for administration by alternative routes to intravenous infusion, such as subcutaneous, intranasal and intramuscular, and for multi-dosing regimes for treatment of chronic conditions.
An active agent comprising an internalization peptide linked to an inhibitor peptide, which inhibits PSD-95 binding to NOS and/or NMDAR2B, wherein the internalization peptide has an amino acid sequence comprising YGRKKRRQRRR (SEQ ID NO:1) and the inhibitor peptide has a sequence comprising KLSSIESDV (SEQ ID NO:2), or a variant thereof with up to five substitutions or deletions total in the internalization peptide and inhibitor peptide, wherein at least the four C-terminal amino acids of the inhibitor peptide are L-amino acids, and a contiguous segment of amino acids including all of the R and K residues are D-amino acids.
The active agent of any preceding claim, wherein the inhibitor peptide comprises [E/D/N/Q]-[S/T]-[D/E/Q/N]-[V/L] (SEQ ID NO:3) at the C-terminus.
The active agent of any preceding claim, wherein the inhibitor peptide comprises I-E-[S/T]-D-V (SEQ ID NO:4) at the C-terminus.
The active agent of any preceding claim, wherein each of the five C-terminal amino acids of the inhibitor peptide are L-amino acids.
The active agent of any preceding claim having enhanced stability in plasma compared with Tat-NR2B9c.
The active agent of any preceding claim having enhanced plasmin resistance compared with Tat-NR2B9c.
The active agent of any preceding claim having a binding affinity for PSD-95 within 2- fold of Tat-NR2B9c.
The active agent of any preceding claim having an IC50 for inhibiting PSD-95 binding to NMDAR2B within 2-fold of Tat-NR2B9c.
The active agent of any preceding claim, which competes with Tat-NR2B9c for binding to PSD-95.
The active agent of any preceding claim as a chloride salt.
A formulation of an active agent of any preceding claim, further comprising histidine and trehalose.
A coformulation comprising the active agent of any preceding claim and an anti-inflammatory agent.
A co-formulation comprising the active agent of any preceding claim and a thrombolytic agent.
A method of treating a subject having or at risk of a condition selected from stroke, cerebral ischemia, traumatic injury to the CNS, subarachnoid hemorrhage, pain, anxiety, epilepsy, comprising administering an effective regime of the active agent of any preceding claim to the subject.
A method of treating ischemic stroke in a subject having or at risk of stroke, comprising administering an effective regime of an active agent to the subject, wherein the subject is co-administered a thrombolytic agent, wherein the active agent comprises an internalization peptide linked to an inhibitor peptide, which inhibits PSD-95 binding to NOS and/or NMDAR2B, wherein at least the four C-terminal amino acids of the inhibitor peptide are L-amino acids, and at least one of the remaining amino acids of the active agent is a D-amino acid, wherein the active agent and thrombolytic agent are administered sufficiently proximate in time that cleavage of the active agent induced by the thrombolytic agent is reduced by the inclusion of the at least one D-amino acid.
The method of any preceding claim, wherein the thrombolytic agent is administered within a window of 60, 30 or 15 minutes before the active agent.
The method of any preceding claim, wherein the active agent and thrombolytic agent are administered at the same time.
A method of delivering an active agent to a subject in need thereof, comprising administering the active agent as defined in any preceding claim by a nonintravenous route, wherein the active agent is delivered to the plasma at a therapeutic level.
Dependencies are inferred from the claim text.